Amgen Inc (AMGN)vsAnheuser Busch Inbev NV ADR (BUD)
AMGN
Amgen Inc
$331.70
+0.79%
HEALTHCARE · Cap: $177.71B
BUD
Anheuser Busch Inbev NV ADR
$79.89
-0.45%
CONSUMER DEFENSIVE · Cap: $159.00B
Smart Verdict
WallStSmart Research — data-driven comparison
Anheuser Busch Inbev NV ADR generates 64% more annual revenue ($60.96B vs $37.22B). AMGN leads profitability with a 21.0% profit margin vs 11.9%. BUD appears more attractively valued with a PEG of 1.78. BUD earns a higher WallStSmart Score of 63/100 (C+).
AMGN
Buy62
out of 100
Grade: C+
BUD
Buy63
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-2.2%
Fair Value
$321.89
Current Price
$331.70
$9.81 premium
Margin of Safety
-9.4%
Fair Value
$70.63
Current Price
$79.89
$9.26 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 101 in profit
Strong operational efficiency at 33.8%
Large-cap with strong market position
Keeps 21 of every $100 in revenue as profit
Generating 1.5B in free cash flow
Large-cap with strong market position
Strong operational efficiency at 26.7%
Earnings expanding 20.3% YoY
Areas to Watch
Expensive relative to growth rate
Trading at 19.5x book value
4.4% earnings growth
Expensive relative to growth rate
Trading at 10.7x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AMGN
The strongest argument for AMGN centers on Return on Equity, Operating Margin, Market Cap. Profitability is solid with margins at 21.0% and operating margin at 33.8%.
Bull Case : BUD
The strongest argument for BUD centers on Market Cap, Operating Margin, EPS Growth. Revenue growth of 12.0% demonstrates continued momentum.
Bear Case : AMGN
The primary concerns for AMGN are PEG Ratio, Price/Book, EPS Growth.
Bear Case : BUD
The primary concerns for BUD are PEG Ratio, Price/Book.
Key Dynamics to Monitor
AMGN profiles as a mature stock while BUD is a value play — different risk/reward profiles.
BUD carries more volatility with a beta of 0.79 — expect wider price swings.
BUD is growing revenue faster at 12.0% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
BUD scores higher overall (63/100 vs 62/100) and 12.0% revenue growth. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Amgen Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. Focused on molecular biology and biochemistry, its goal is to provide a healthcare business based on recombinant DNA technology.
Visit Website →Anheuser Busch Inbev NV ADR
CONSUMER DEFENSIVE · BEVERAGES - BREWERS · USA
Anheuser-Busch InBev SA / NV is engaged in the production, distribution and sale of beer, alcoholic beverages and soft drinks worldwide.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?